Founders at Work Speaker Series with Regencor:
"Cardiac Regenerative Therapeutics Using Cell-Free Biologics"
November 5, 2019 from 12:00 to 1:00 PM
MBC BioLabs San Carlos
Please join Amgen and Regencor co-founder, Pilar Ruiz-Lozano, for the next Founders-At-Work Speaker Series where entrepreneurs connect, share their stories and talk about science!

As a member of the Faculty at Stanford School of Medicine, Dr. Ruiz-Lozano pioneered the development of tissue engineering and epicardial biology to treat heart disease.  She led the discovery of the cardiac regenerative properties of recombinant human FSTL1 and the development of delivery modalities that are now licensed by Regencor, Inc.
Founders at Work Speaker Series with Caribou Biosciences:
"Next-generation gene editing technology for allogeneic immune cell therapeutics"
November 20, 2019 from 12:30 to 1:30 PM
MBC BioLabs San Francisco
Please join Caribou Biosciences co-founder, Rachel Haurwitz, for the next Founders-At-Work Speaker Series where entrepreneurs connect, share their stories and talk about science!

Rachel Haurwitz is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Celldom, Inc., founded in 2016 in Durham, North Carolina, is developing next generation, single-cell analysis technology to advance research, drug discovery and development by illuminating diversity in cell populations.

The science behind CuraX is based on the game-changing discovery at Stanford of a new target that is relevant to stopping a range of neurodegenerative diseases, starting with Parkinson's disease (PD), currently impossible with any drug on the market. We have shown that reducing this new target is indeed neuroprotective in multiple model systems. We have already identified promising small molecules by high-throughput and in silico screens. We plan to optimize the lead compounds that fit the human blood-brain barrier penetrant profile, select the development candidate and move forward to clinical trials.

ExcepGen is developing better therapeutics by using authentic human proteins in drug discovery. With its novel platform, the company is discovering antibodies against previously impossible targets and pursuing new therapeutic proteins.

Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage. We are targeting a class of pathological age associated compounds termed Advanced Glycation End Products (AGEs) which build up on long lived proteins like collagen. AGE accumulation is implicated in multiple diseases of aging, thus Revel Pharmaceuticals is strategically position to develop therapeutics across multiple indications.